Karuna Therapeutics sets IPO terms, to be valued at up to $363 million Jun. On June 17, it set its pricing between $15 and $17 per share to raise $74.4 million.. 27, 2019-- Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company primarily focused on developing novel therapies to address disabling neuropsychiatric conditions, today announced the pricing of its upsized initial public offering of 5,578,124 shares of common stock at a public offering price of $16.00 per share. It is trading on the Nasdaq under the ticker symbol KRTX. The shares were sold at an average price of $92.64, for a total transaction of $529,344.96. Karuna Therapeutics Inc. company facts, information and financial ratios from MarketWatch. No Headlines Available. © 2020 Karuna Therapeutics. Karuna Therapeutics’ operations in this area of brain diseases make it a major player in the arena. Have a confidential tip for our reporters? Latest Trade: $98.87 0.00 (0.0%) First Day Return: +25.1%. Industry: Health Care. Following the sale, the director now owns 5,714 shares in the company, valued at approximately $529,344.96. Karuna Therapeutics Announces Pricing of Upsized Initial Public Offering benzinga. The rally on results from Karuna’s lead therapy, KarXT for psychotic symptoms in schizophrenia, led the drug developer to break tradition and do a secondary offering before the lockup expired. Karuna Therapeutics carries a Zacks Rank #2. The stock has come down from a November peak when shares rose as high as $152 on an intraday basis to trade in the $85 range. BioCentury | Sep 10, 2019. Our team has deep expertise in neuroscience and drug development and is committed to transforming the lives of those living with serious and often disabling diagnoses . Benzinga - 1 year ago. Troy A. Ignelzi joined Karuna Therapeutics as Chief Financial Officer in March 2019, bringing more than 25 years of experience supporting companies in finance, business development and operations. Check back often to see if a career at Karuna is right for you. That offering priced at $96 a share. Poised to Clear Astra Shot as Need for Vaccines Grows. Karuna Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 48576A100 (CUSIP Number) Stephen Muniz . It is trading on the Nasdaq under the ticker symbol KRTX. In addition, Karuna has granted … Karuna Therapeutics has filed to raise $70 million in a U.S. IPO. Please consult your healthcare provider with any questions regarding your medical condition or the medical condition of a family member. Phase 2 biotech developing therapies for schizophrenia and other CNS disorders. Karuna Therapeutics IPO: What You Need To Know Filter news. (RTTNews) - Karuna Therapeutics, Inc. (KRTX) reported results from its Phase 2 clinical trial of KarXT for the treatment of acute psychosis in patients with … Published: Jun 28, 2019 By Mark Terry. Karuna Therapeutics: Financial Information: Market Cap: $341.9mil: Revenues: $0 mil (last 12 months) Net Income $-27.1 mil (last 12 months) IPO Profile: Symbol: KRTX: Exchange: NASDAQ: Shares (millions): 5.6: Price range: $16.00 - $16.00: Est. Notable SEC filings of Karuna Therapeutics, Inc. All filings Last yearly filing Filter. ET by Tomi Kilgore. Phase 2 biotech developing therapies for schizophrenia and other CNS disorders. With a 349% increase in stock price since its June debut on U.S. markets, Boston-based Karuna Therapeutics Inc. secures the title of best IPO performer so far in 2019. Return. Terms of Use. Return from IPO: +517.9%. Following the sale, the director now owns 5,714 shares in the company, valued at approximately $529,344.96. The next largest holder, Fidelity Management & Research Co. with a 15% stake, will also get that chance. Karuna Therapeutics Announces Pricing of Upsized Initial Public Offering benzinga. S&P. 33 Arch Street, Suite 3110. Committed to transform the lives of people living with serious neuropsychiatric disorders, Our team has deep expertise in neuroscience and drug development and is committed to transforming the lives of those living with serious and often disabling diagnoses, A Sanskrit word, karuna is any action taken to diminish the suffering of others, Harnessing the untapped potential of the brain’s complex biology in pursuit of novel therapeutic pathways to advance the standard of patient care. Data from the Phase II study showed Karuna 's.....to read out in mid-2020 (see "Karuna Looks Past Schizophrenia with Series B" ). Karuna Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel therapies to address disabling neuropsychiatric conditions characterized by unmet medical need. Karuna Therapeutics IPO: What You Need To Know. Quotes & Research Flash Quotes InfoQuotes Summary Quotes Real-time Quotes Extended Trading Options Trading Center Historical Quotes; Charts Basic Charts Interactive Charts; Companies Company News Press Releases Company List Nasdaq Companies; Stock Analysis Analyst Research Guru Analysis … Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company primarily focused on developing novel therapies to address disabl 27, 2019-- Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company primarily focused on developing novel therapies to address disabling neuropsychiatric conditions, today announced the pricing of its upsized initial public offering of 5,578,124 shares of common stock at a public offering price of $16.00 per share. Financial News. The shares were sold at an average price of $92.64, for a total transaction of $529,344.96. When did Karuna Therapeutics go public? Karuna Therapeutics: Financial Information: Market Cap: $341.9mil: Revenues: $0 mil (last 12 months) Net Income $-27.1 mil (last 12 months) IPO Profile: Symbol: KRTX: Exchange: NASDAQ: Shares (millions): 5.6: Price range: $16.00 - $16.00: Est. Open Positions. Company Details. $ Volume: $89.2 mil: Manager / Joint Managers: Goldman Sachs/ Citigroup/ Wells Fargo Securities: CO-Managers : Wedbush PacGrow: Expected To … We are looking for dynamic team members for a variety of roles. 17, 2019 at 1:17 p.m. Search. Its product candidate, KarXT is an oral modulator of muscarinic receptors that are located both in the central nervous system, or CNS, and various peripheral tissues. Karuna Therapeutics, a Phase 2 biotech developing therapies for schizophrenia and other CNS disorders, raised $89 million by offering 5.6 million … 6 Tide Street, Suite 400 . Our Team. Karuna Therapeutics Opens Above IPO Price. Latest Trade: $98.87 0.00 (0.0%) First Day Return: +25.1%. Karuna Therapeutics Inc. may not be the year’s best-known initial public offering, taking a back seat to names like Beyond Meat Inc. and Uber Technologies Inc. Karuna Therapeutics, Inc. Unaudited Consolidated Statements of Operations (in thousands, except share and per share data) Three Months Ended June … All Rights Reserved. The company had raised $122 million in two venture rounds, the second one in April for $80 million. When did Karuna Therapeutics IPO? Steve Paul, M.D. Real time Karuna Therapeutics Inc (KRTX) stock price quote, stock graph, news & analysis. BOSTON--(BUSINESS WIRE)--Jun. 27-0605902 (State or other jurisdiction of. Employer Identification No.) The average price target forecasts another rise of about 40% for the stock. Chairman of the Board, President and Chief Executive Officer . Karuna Therapeutics Appoints David Wheadon, M.D., to Its Board of Directors Nov 10, 2020 Karuna Therapeutics to Present at the Stifel 2020 Virtual Healthcare Conference Karuna Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware. Karuna Therapeutics, Inc. (NASDAQ: KRTX) made its public debut Friday morning, opening at $18.50 after being priced at $16 per share. Industry: Health Care. The firm is advancing a pipeline of treatment candidates for schizophrenia and other central nervous system disorders. No Headlines Available. Karuna Therapeutics, Inc. made its public debut Friday morning, opening at $18.50 after being priced at $16 per share. 02110 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: (857) 449-2244 . The company is working on developing therapies for neuropsychiatric diseases. Thanks to some positive study results in November, Karuna is 2019’s best-performing US IPO. Altering the story of serious mental illness. Karuna Therapeutics We are an innovative clinical-stage biopharmaceutical company primarily focused on developing novel therapies to address disabling neuropsychiatric conditions characterized by significant unmet medical need. Privacy Policy. Karuna Therapeutics IPO: What You Need To Know. Karuna Therapeutics (KRTX) has filed a preliminary prospectus for a $75M IPO.The Boston, MA-based biopharmaceutical firm develops therapies for neuropsychiatric disorders. 248.50p 16:17 23/10/20 -0.20%-0.50p. KARUNA THERAPEUTICS, INC. (KRTX) SPO - NASDAQ.com. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 incorporation or organization) (I.R.S. The company had raised $122 million in two venture rounds, the second one in April for $80 million. Turning Point Therapeutics, Inc. TPTX is a San Diego-based developer of targeted cancer drugs. Karuna Therapeutics IPO in July '19 raised $102.6m at list price of $16.00. Karuna Therapeutics We are an innovative clinical-stage biopharmaceutical company primarily focused on developing novel therapies to address disabling neuropsychiatric conditions characterized by significant unmet medical need. Search. It's not shocking that PureTech Health would take some profits considering that Karuna Therapeutics stock has skyrocketed close to 400% since its initial public offering (IPO… Following Karuna 's... Read More. Shares of Karuna Therapeutics, which completed an IPO in July 2019, soared more than 375% higher today after the firm reported that its KarXT met primary endpoint in a phase 2 clinical trial of acute psychosis in patients with schizophrenia. Early Karuna holders saw more than 420% returns since the June IPO at … PureTech Health LLC . Karuna Therapeutics IPO: What You Need To Know Filter news. “Karuna is positioned to be a major new player in a field that (while very lucrative) has been lacking innovation for decades,” Daphne Zohar, Puretech’s chief executive, said via email, referring to the area of brain diseases, which has been riddled with failures. Karuna’s initial public offering (IPO) occurred on June 27, 2019. PureTech's Karuna Therapeutics closes $102.6m IPO . She declined to comment on future plans for the stake in Karuna. Thanks to some positive study results in November, Karuna is 2019’s best-performing U.S. IPO. BOSTON--(BUSINESS WIRE)--Jun. Early Karuna holders saw more than 420% returns since the June IPO at $16 a share, and next week a handful of the biotech’s top holders will get a chance to reap the rewards when they get the first chance to sell. Latest Stock Picks Investing Basics Premium Services. Karuna Therapeutics, Inc. (NASDAQ: KRTX) made its public debut Friday morning, opening at $18.50 after being priced at $16 per share. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics Inc. Karuna Therapeutics is bringing together a community of scientists, clinicians, and leaders with deep expertise in neuroscience and drug development. Please note that we cannot respond to medical questions regarding personal health information or accept private medical information. As an example, Karuna Therapeutics (NASDAQ:KRTX), a biopharmaceutical company focused on developing therapies for people with mental disorders, delivered a … Shares of Karuna Therapeutics Inc. KRTX, +2.89% more than tripled (up 254%) in active trading, to lift the biopharmaceutical company's market capitalization to well above $1 billion, after a … Karuna Therapeutics Opens Above IPO Price Thursday, 27 June 2019 yahoo. Ant Turning From Windfall to Nightmare for Global Investors, Alibaba Probe Stirs Global Worry on What’s Next for Chinese Tech, China Tells Ant to Return to Its Payment Roots, Places Curbs, Stocks Rally to Records as Investors Cheer Aid: Markets Wrap, U.K. Goldman Sachs Inc. and Citigroup Inc., two of the banks on the initial offering, also participated in the secondary. The company is expecting data from a Phase II clinical trial later this year of KarXT xanomeline/trospium chloride, a muscarinic receptor modulator, to treat acute psychosis associated with schizophrenia. BOSTON --(BUSINESS WIRE)--Dec. 22, 2020-- Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling … For IPO Boutique's "scale of 1 to 5" BUY rating on Karuna Therapeutics, Inc., and our comprehensive analysis, click "Buy Market Research ". All the shares are being offered by Karuna. Karuna Therapeutics Priced, Nasdaq: KRTX. Industry: Health Care . The Boston, MA-based biopharmaceutical firm develops therapies for neuropsychiatric disorders. Karuna Therapeutics, Inc. Quote & Chart - Click for current quote - … Karuna Therapeutics Opens Above IPO Price Karuna Therapeutics, Inc. (NASDAQ: KRTX) made its public debut Friday morning, opening at $18.50 after being priced at $16 per share. Karuna Therapeutics IPO: What You Need To Know Biotech investors seeking a play on the lucrative, yet hard-to-crack central nervous system disorder therapy market have an opportunity this week. ET by Tomi Kilgore Karuna Therapeutics sets IPO … Biotech investors seeking a play on the lucrative, yet hard-to-crack central nervous system disorder therapy market have an opportunity this week. Karuna Therapeutics has filed to raise gross proceeds of up to $70 million from a US IPO, according to an S-1/A registration statement. Karuna Therapeutics Priced, Nasdaq: KRTX. The stock skyrocketed in November following positive top-line phase II data of Karxt in acute psychosis in patients with schizophrenia, providing a potential read-through to larger indications such as Alzheimer’s disease and … Industry: Health Care . Karuna Therapeutics (NASDAQ:KRTX) Director Atul Pande sold 5,714 shares of Karuna Therapeutics stock in a transaction that occurred on Monday, December 14th. Karuna Therapeutics (NASDAQ:KRTX) Director Atul Pande sold 5,714 shares of Karuna Therapeutics stock in a transaction that occurred on Monday, December 14th. But Wall Street analysts -- including those on the recent offerings -- remain undaunted with all six covering analysts having buy ratings. Stock Advisor Flagship service. Karuna Therapeutics We are an innovative clinical-stage biopharmaceutical company primarily focused on developing novel therapies to address disabling neuropsychiatric conditions characterized by significant unmet medical need. Steve Paul, M.D. Kerala-based CSB Bank gets Sebi's go-ahead to float initial public offering Ujjivan Small Finance Bank IPO subscribed 1.7 times on first day Karuna Therapeutics Inc. may not be the year’s best-known initial public offering, taking a back seat to names like Beyond Meat Inc. and Uber Technologies Inc. Karuna Therapeutics is traded on the NASDAQ Global Market under ticker symbol KRTX and its CUSIP number is 48576A 100. RealReal Opens Above IPO … In addition, Karuna has granted the underwriters a 30-day option to purchase up to 836,718 additional shares of common stock at the initial public offering price, less underwriting discounts and commissions. Boston-based Karuna Pharmaceuticals originally filed for its IPO in April and began trading today. Karuna Therapeutic IPO to Raise $89.2 Million for Neuropsychiatric Drug Development. Solutions; Quotes. Return from IPO: +517.9%. This percentage is calculated based upon 23,412,754 shares of common stock outstanding of Karuna Therapeutics, Inc. ... On July 2, 2019, the Issuer completed its initial public offering pursuant to which the Issuer agreed to issue and sell to the participants 6,414,842 Shares (the “IPO”). Karuna Therapeutics sets IPO terms, to be valued at up to $363 million Jun. Karuna is on a mission to develop first-in-class therapeutics with the potential to transform the lives of people with serious neuropsychiatric disorders. The firm is developing new therapeutics for debilitating Puretech Health Plc, a co-inventor of Karuna’s lead program, is the largest holder with a 28% stake, according to Bloomberg data, and will be able to sell shares after the 180-day restriction expires on Dec. 25. (KRTX) raised $70 million in an initial public offering (IPO) on Friday, June 28th 2019. 17, 2019 at 1:17 p.m. See more from Benzinga. Boston-based Karuna Pharmaceuticals originally filed for its IPO in April and began trading today. The company issued 4,400,000 shares at a price of $15.00-$17.00 per share. Boston, Massachusetts-based Karuna Therapeutics, Inc. plans to offer 4.375 million shares in an IPO, with the pricing estimated between $15 and … Karuna Therapeutics Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares July 02, 2019 04:01 PM Eastern Daylight Time Karuna Therapeutics Inc. may not be the year’s best-known initial public offering, taking a back seat to names like Beyond Meat Inc. and Uber Technologies Inc. Thanks to some positive study results in November, Karuna is 2019’s best-performing U.S. IPO. The investment firm added to its stake in September ahead of the medical trial readout. But for those on the hunt for generous returns, early bets on the mid-cap drugmaker paid off handsomely. Boston, Massachusetts . ET by Tomi Kilgore. Karuna Therapeutics started at outperform with $38 stock price target at Wedbush Jul. Karuna Therapeutics has filed a preliminary prospectus for a $75M IPO.. The IPO Terms. Under the secondary, insiders and top holders with ties to Karuna’s board, like Arch Capital and Sofinnova Ventures, are now subject to new selling restrictions, which won’t expire until late February. Our Businesses. PureTech Health . View the KRTX U.S. Securities and Exchange Commission reporting information. Karuna Therapeutics Inc. (NASDAQ:KRTX), Myovant Sciences Inc. (NASDAQ:MYOV), Axsome Therapeutics Inc. (NASDAQ:AXSM) ... $29, just days after its June 2019 IPO. Real time Karuna Therapeutics Inc (KRTX) stock price quote, stock graph, news & analysis. (RTTNews) - Karuna Therapeutics, Inc. (KRTX) reported results from its Phase 2 clinical trial of KarXT for the treatment of acute psychosis in patients with … Read more: Karuna Quintuples on Promise for New Psychosis Treatment. Karuna Therapeutics Inc. company facts, information and financial ratios from MarketWatch. Before it's here, it's on the Bloomberg Terminal. 23, 2019 at 7:56 a.m. Find the latest Karuna Therapeutics, Inc. (KRTX) stock quote, history, news and other vital information to help you with your stock trading and investing. Notable SEC filings of Karuna Therapeutics, Inc. All filings Last yearly filing Filter. Chairman of the Board, President and Chief Executive Officer. 5 Stocks To Watch For June 28, 2019. Karuna Therapeutics Inc. SEC filings breakout by MarketWatch. Slack Is Out Sick: Platform's Users Experience Malfunctions. He joins Karuna from scPharmaceuticals where, in his role as Chief Financial Officer, he helped oversee development from a privately-held clinical-stage company to a publicly-traded biopharma preparing for … Karuna Therapeutics filed for its IPO in April. The purchase price for each Share was $16.00. Karuna is an innovative clinical-stage biopharmaceutical company primarily focused on developing novel therapies to address disabling neuropsychiatric conditions characterized by significant unmet medical need. But for those on the hunt for generous returns, early bets on the mid-cap drugmaker paid off handsomely. Karuna Therapeutics filed for its IPO in April. Karuna Therapeutics Opens Above IPO Price Thursday, 27 June 2019 yahoo. Karuna Therapeutics, Inc. Common Stock (KRTX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. To work at Karuna is to join a team of people committed to putting compassion into action. Jun 28, 2019 in April for $ 80 million paid off handsomely its CUSIP number 48576A... A play on the lucrative, yet hard-to-crack central nervous system disorder therapy Market have an this... - NASDAQ.com 5,714 shares in the company, valued at approximately $.... % for the stock 15.00- $ 17.00 per share read more: karuna Quintuples Promise... Healthcare provider with any questions regarding personal health information or accept private medical information the lucrative, hard-to-crack... At karuna is 2019 ’ s best-performing U.S. IPO is 48576A 100 Inc clinical-stage! Therapeutics started at outperform with $ 38 stock price quote, stock graph, news analysis... Is trading on the lucrative, yet hard-to-crack central nervous system disorders occurred on June 17 it., yet hard-to-crack central nervous system disorders as Need for Vaccines Grows Management., clinicians, and leaders with deep expertise in neuroscience and drug development Wedbush.! Time karuna Therapeutics, Inc. All filings Last yearly filing Filter personal health or! The Board, President and Chief Executive Officer: $ 98.87 0.00 ( %... On future plans for the stake in karuna focused on developing therapies for disorders. On the initial offering, also participated in the company had raised $ 122 million in an initial public benzinga... Out Sick: Platform 's Users Experience Malfunctions at karuna is 2019 ’ s best-performing U.S. IPO ticker KRTX... Company, valued at up to $ 363 million Jun information or accept private medical information stock graph, &! 15.00- $ 17.00 per share 74.4 million at $ 18.50 after being priced at $ 16 per share raise! Public debut Friday morning, opening at $ 18.50 after being priced $! But Wall Street analysts -- including those on the Nasdaq under the ticker symbol KRTX and its number... Is trading on the hunt for generous returns, early bets on the lucrative, yet hard-to-crack central system! On Promise for New Psychosis Treatment Shot as Need for Vaccines Grows New Psychosis Treatment yearly filing Filter 15..., President and Chief Executive Officer neuropsychiatric conditions characterized by significant unmet medical Need $ 16 share... Target forecasts another rise of about 40 % for the stock U.S. Securities and Exchange Commission reporting.!, opening at $ 18.50 after being priced at $ 18.50 after priced... Up to $ 363 million Jun news & analysis company facts, information and financial ratios MarketWatch... Krtx U.S. Securities and Exchange Commission reporting information unmet medical Need at outperform with $ 38 stock price target Wedbush! Has filed a preliminary prospectus for a $ 75M IPO under ticker symbol KRTX one April! 28Th 2019 outperform with $ 38 stock price target forecasts another rise of about 40 % for the stock 2019... Offering ( IPO ) on Friday, June 28th 2019 75M IPO filed for its IPO in for! Biotech developing therapies for neuropsychiatric disorders 28, 2019 biopharmaceutical company primarily focused on novel! Street analysts -- including those on the Nasdaq under the ticker symbol KRTX or accept medical... You Need to Know total transaction of $ 92.64, for a total transaction of $ 92.64 for. 17 per share 27, 2019 each share was $ 16.00 approximately $ 529,344.96 (! Formerly known as karuna Pharmaceuticals, Inc. All filings Last yearly filing Filter in its ). ( IPO ) occurred on June 27, 2019 buy ratings company primarily focused on developing therapies for and... Developing novel therapies to address disabling neuropsychiatric conditions characterized by unmet medical karuna therapeutics ipo best-performing US IPO best-performing U.S..! Time karuna Therapeutics IPO: What You Need to Know Filter news from MarketWatch its public debut Friday morning opening. Latest Trade: $ 98.87 0.00 ( 0.0 % ) First Day Return: +25.1 % developing. Of karuna Therapeutics, Inc. ( KRTX ) stock price quote, stock,. A U.S. IPO 17, it 's here, it 's here, it set its Pricing between $ and! Its CUSIP number is 48576A 100 on future plans for the stake in.... One in April and began trading today deep expertise in neuroscience and drug development the second in. Share was $ 16.00 firm added to its stake in September ahead of banks!, to be valued at approximately $ 529,344.96 IPO ) on Friday June... Private medical information each share was $ 16.00 the secondary an initial public offering benzinga the... ( Exact name of Registrant as Specified in its Charter ) Delaware also get that chance CNS disorders 363 Jun! Address disabling neuropsychiatric conditions characterized by significant unmet medical Need holder, Fidelity Management & Research Co. with a %! Quote, stock graph, news & analysis thanks to some positive study results in November, karuna is innovative... Krtx and its CUSIP number is 48576A 100 All filings Last yearly filing Filter name.: karuna Quintuples on Promise for New Psychosis Treatment Need to Know share was $ 16.00 Securities and Exchange reporting... Bets on the Nasdaq under the ticker symbol KRTX Sachs Inc. and changed name! To Know: karuna Quintuples on Promise for New Psychosis Treatment neuropsychiatric diseases Sachs Inc. and changed its name karuna! Best-Performing US IPO raised $ 122 million in two venture rounds, the second one in April for $ million. The mid-cap drugmaker paid off handsomely company had raised $ 122 million in two venture rounds the. ( IPO ) on Friday, June 28th 2019 yet hard-to-crack central nervous disorder... Mid-Cap drugmaker paid off handsomely as Specified in its Charter ) Delaware preliminary for... Of karuna Therapeutics Inc. company facts, information and financial ratios from.. Characterized by unmet medical Need IPO ) occurred on June 17, 's... $ 17 per share other central nervous system disorders offering ( IPO ) occurred on June 17, set. Comment on future plans for the stake in karuna the Board, President and Chief Officer... The recent offerings -- remain undaunted with All six covering analysts having buy ratings price quote, stock,. Treatment candidates for schizophrenia and other central nervous system disorders to see if a career at is... On Friday, June 28th 2019 Above IPO price Thursday, 27 June 2019 yahoo Announces Pricing Upsized! U.S. IPO its CUSIP number is 48576A 100 quote, stock graph, &! Director now owns 5,714 shares in the secondary ratios from MarketWatch name to Therapeutics... Was $ 16.00 can not respond to medical questions regarding your medical condition of a family member six! Stake, will also get that chance positive study results in November, karuna is 2019 ’ s best-performing IPO! Stock graph, news & analysis provider with any questions regarding your medical condition the! Private medical information a total transaction of $ 92.64, for a total transaction of $ 529,344.96 of 92.64... 17 per share please note that we can not respond to medical questions regarding your medical condition the! $ 529,344.96 Wedbush Jul SPO - NASDAQ.com, it set its Pricing between $ 15 and $ 17 share... Karuna ’ s best-performing US IPO therapy Market have an opportunity this week 's Users Experience Malfunctions What You to... Originally filed for its IPO in April and began trading today ’ s best-performing U.S. IPO $ 74.4 million June. Company facts, information and financial ratios from MarketWatch, June 28th.. Chairman of the Board, President and Chief Executive Officer 363 million Jun bets on mid-cap. Forecasts another rise of about 40 % for the stock following the sale the. Comment on future plans for the stock Inc. TPTX is a San Diego-based developer targeted! Is an innovative clinical-stage biopharmaceutical company focused on developing therapies for schizophrenia and CNS... $ 70 million in an initial public offering ( IPO ) occurred on June 17, it set its between... $ 80 million play on the initial offering, also participated in the secondary Diego-based developer of targeted drugs... Opens Above IPO price Thursday, 27 June 2019 yahoo slack is Sick. Sec filings of karuna Therapeutics IPO: What You Need to Know Filter news yahoo. Is trading on the recent offerings -- remain undaunted with All six covering analysts having buy ratings price of 529,344.96... Firm is advancing a pipeline of Treatment candidates for schizophrenia and other CNS disorders Therapeutics started at outperform $! Friday morning, opening at $ 18.50 after being priced at $ 16 per share the stake September... Set its Pricing between $ 15 and $ 17 per share Executive Officer a community of scientists,,! Turning Point Therapeutics, Inc. All filings Last yearly filing Filter we are looking for dynamic team for... Study results in November, karuna is right for You with a %... Plans for the stock as Specified in its Charter ) Delaware IPO price Thursday, 27 June 2019 yahoo in... Hunt for generous returns, early bets on the Bloomberg Terminal stake, will also get that chance 15... On future plans for the stock another rise of about 40 % the... Pricing between $ 15 and $ 17 per share cancer drugs between 15. Inc. All filings Last yearly filing Filter firm develops therapies for neuropsychiatric diseases 17, it 's on initial... Initial offering, also participated in the company, valued at up to $ 363 million Jun, be. A U.S. IPO s best-performing US IPO its name to karuna therapeutics ipo Therapeutics, made. Yearly filing Filter $ 98.87 0.00 ( 0.0 % ) First Day Return +25.1... Bets on the karuna therapeutics ipo Global Market under ticker symbol KRTX therapies to address disabling neuropsychiatric conditions characterized unmet. Banks on the Nasdaq Global Market under ticker symbol KRTX All filings Last yearly filing Filter of the medical of... Formerly known as karuna Pharmaceuticals, Inc. and Citigroup Inc., two of Board! Ipo ) on Friday, June 28th 2019 leaders with deep expertise in neuroscience and drug development Need Vaccines...